
    
      This is a single arm, open-label, single-center study. This study is indicated for LMP1
      positive infectious diseases and hematological malignancies. The selections of dose levels
      and the number of subjects are based on clinical trials of similar foreign products. 144
      patients will be enrolled. Primary objective is to explore the safety, main consideration is
      dose-related safety.
    
  